Patients characteristics related to screening mammography cancellation and rescheduling rates during the COVID-19 pandemic

Amornsiripanitch, Nita; Chikarmane, Sona A.; Bay, Camden; Giess, Catherine S.

doi:10.1016/j.clinimag.2021.07.009

Cited by 15 publications

(24 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An initial 2451 citations were identified for title and abstract screening, of which 77 were eligible for inclusion ( Fig. 1 ) [ [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] , [28] , [29] , [30] , [31] , [32] , [33] , [34] , [35] , [36] , [37] , [38] , [39] , [40] , [41] , [42] , [43] , [44] , [45] , [46] , [47] , [48] , [49] , [50] , [51] , [52] , [53] , [54] , [55] , [56] , [57] , [58] , [59] , [60] , [61] , [62] , [63] , [64] , [65] , [66] , [67] , [68] , [69] , [70] , [71] , [72] , [73] , [74] , [75] ,…”

Section: Resultsmentioning

confidence: 99%

A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis

Nickel²,

Ngo³

et al. 2023

The Breast

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis

Nickel²,

Ngo³

et al. 2023

The Breast

View full text Add to dashboard Cite

“…Additionally, although lung cancer was the second most common disease site selected, the projected impact will be less than that for all the other sites, likely because screening for lung cancer is relatively new with low uptake 23 . Lastly, although some may think that missing annual breast screening may not pose problems, each year roughly 40% of eligible people miss routine screening, and the screening deficit associated with the COVID‐19 pandemic could potentially exacerbate this disparity 24‐27 …”

Section: Discussionmentioning

confidence: 99%

“…23 Lastly, although some may think that missing annual breast screening may not pose problems, each year roughly 40% of eligible people miss routine screening, and the screening deficit associated with the COVID-19 pandemic could potentially exacerbate this disparity. [24][25][26][27] Our study has several limitations. First, these preliminary results from accredited cancer programs may not represent the broader national experience even though they represent a large sample size.…”

Section: B C Dmentioning

confidence: 99%

A national quality improvement study identifying and addressing cancer screening deficits due to the COVID‐19 pandemic

Joung

Nelson

Mullett

et al. 2022

Cancer

View full text Add to dashboard Cite

BACKGROUND: Cancer-related deaths over the next decade are expected to increase due to cancer screening deficits associated with the coronavirus disease 2019 (COVID-19) pandemic. Although national deficits have been quantified, a structured response to identifying and addressing local deficits has not been widely available. The objectives of this report are to share preliminary data on monthly screening deficits in breast, colorectal, lung, and cervical cancers across diverse settings and to provide online materials from a national quality improvement (QI) study to help other institutions to address local screening deficits. METHODS: This prospective, national QI study on Return-to-Screening enrolled 748 accredited cancer programs in the United States from April through June 2021. Local prepandemic and pandemic monthly screening test volumes (MTVs) were used to calculate the relative percent change in MTV to describe the monthly screening gap. RESULTS: The majority of facilities reported monthly screening deficits (colorectal cancer, 80.6% [n = 104/129]; cervical cancer, 69.0% [n = 20/29]; breast cancer, 55.3% [n = 241/436]; lung cancer, 44.6% [n = 98/220]). Overall, the median relative percent change in MTV ranged from -17.7% for colorectal cancer (interquartile range [IQR], -33.6% to -2.8%), -6.8% for cervical cancer (IQR, -29.4% to 1.7%), -1.6% for breast cancer (IQR, -9.6% to 7.0%), and 1.2% for lung cancer (IQR, -16.9% to 19.0%). Geographic differences were not observed. There were statistically significant differences in the percent change in MTV between institution types for colorectal cancer screening (P = .02). CONCLUSION: Cancer screening is still in need of urgent attention, and the screening resources made available online may help facilities to close critical gaps and address screenings missed in 2020.

show abstract

“…Similar to our local experience, screening mammography rates nationally increased and remain elevated once moratoriums were removed despite the persistence of COVID, although underserved populations are less likely to resume screening or more likely to cancel and not reschedule (19)(20)(21). We planned for the resumption of screening almost as soon as the moratorium started, due to recognition of the importance of planning and messaging (22,23).…”

Section: Discussionmentioning

confidence: 61%

The Influence of Screening Mammography Cessation and Resumption on Breast Cancer Presentation and Treatment: A Multi-Hospital Health System Experience During the Early COVID-19 Pandemic

Mason¹,

Friedrich²,

Niakan³

et al. 2022

EJBH

View full text Add to dashboard Cite

Objective: To assess the impact of the coronavirus disease-2019 (COVID-19) pandemic screening restrictions on the diagnosis and treatment of breast cancer in a single health system. Materials and Methods:We performed a retrospective, cohort investigation of breast cancer patients at a multi-institution health system from March 1, 2019 to December 31, 2020 with two time periods related to the pandemic: "Early phase" (March 18 -June 7) reflecting the time of the screening mammography moratorium and "Late phase" (June 8 -December 31) to reflect the time once screening mammography resumed. 2020 was compared to 2019 to exclude potential differences from temporal or seasonal changes. Variables included demographics, COVID related-deferral, cancer specific data, method of detection, type of treatment recommended and received.Results: Fewer patients presented with a breast cancer diagnosis during Early phase 2020 when compared to any other time period. Numbers increased significantly in Late phase 2020; total numbers of patients seen in 2020 approached but did not completely reach that of 2019. When compared to other time periods, patients who presented during the moratorium on screening were younger, more likely to be black, had a higher Body Mass Index, and were more likely to have a human epidermal growth factor receptor 2 positive tumor. There was a slight increase in size of presenting tumor and node positivity, although no differences in breast or axillary surgical management were identified. Conclusion:Despite an increase in tumor size and positive nodal status seen during the screening moratorium, surgical treatment was not negatively impacted.

show abstract

Patients characteristics related to screening mammography cancellation and rescheduling rates during the COVID-19 pandemic

Cited by 15 publications

References 23 publications

A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis

A systematic review of the impact of the COVID-19 pandemic on breast cancer screening and diagnosis

A national quality improvement study identifying and addressing cancer screening deficits due to the COVID‐19 pandemic

The Influence of Screening Mammography Cessation and Resumption on Breast Cancer Presentation and Treatment: A Multi-Hospital Health System Experience During the Early COVID-19 Pandemic

Contact Info

Product

Resources

About